Glenview Capital Management 13F, Q1 2024
Larry Robbins · quarter ending 31 March 2024 · filed 15 May 2024 · SEC CIK 1138995
Common stock only: shares the fund reported owning at the quarter end, valued as filed. The filing also lists 2 put and call lines, reported at the value of the underlying shares; they are not ownership and are not in these totals.
Largest positions, Q1 2024
The 25 largest of 43 positions. Weights are against the whole filed book. Changes are in shares held, against the Q4 2023 filing.
| Company | Ticker | Value | % of book | vs Q4 2023 |
|---|---|---|---|---|
| TENET HEALTHCARE CORP | THC | $665.05M | 13.0% | -18% shares |
| THE CIGNA GROUP | CI | $534.46M | 10.4% | -31% shares |
| CORTEVA INC | CTVA | $391.36M | 7.6% | +44% shares |
| UNIVERSAL HLTH SVCS INC | UHS | $374.87M | 7.3% | +21% shares |
| GLOBAL PMTS INC | GPN | $319.21M | 6.2% | +23% shares |
| ALIGHT INC | ALITEUR | $279.00M | 5.4% | +56% shares |
| DXC TECHNOLOGY CO | DXC | $271.13M | 5.3% | unchanged |
| ELEMENT SOLUTIONS INC | ESI | $208.80M | 4.1% | +122% shares |
| CLARIVATE PLC | $183.16M | 3.6% | unchanged | |
| MCKESSON CORP | MCK | $154.59M | 3.0% | -12% shares |
| US FOODS HLDG CORP | USFD | $136.23M | 2.7% | +44% shares |
| CVS HEALTH CORP | CVS | $135.31M | 2.6% | +127% shares |
| FISERV INC | FISV | $128.29M | 2.5% | -15% shares |
| TEVA PHARMACEUTICAL INDS LTD | TEVA | $105.84M | 2.1% | +368% shares |
| MYRIAD GENETICS INC | MYGN | $105.40M | 2.0% | -6% shares |
| MARVELL TECHNOLOGY INC | MRVL | $97.15M | 1.9% | +663% shares |
| BROOKDALE SR LIVING INC | BKD | $95.48M | 1.9% | -15% shares |
| ELEVANCE HEALTH INC | ELV | $90.34M | 1.8% | +360% shares |
| UBER TECHNOLOGIES INC | UBER | $86.91M | 1.7% | -43% shares |
| EXPEDIA GROUP INC | EXPE | $84.64M | 1.6% | -12% shares |
| KNIGHT-SWIFT TRANSN HLDGS IN | KNX | $72.90M | 1.4% | +55% shares |
| VALVOLINE INC | VVV | $72.83M | 1.4% | -30% shares |
| AMAZON COM INC | AMZN | $72.68M | 1.4% | -42% shares |
| HCA HEALTHCARE INC | HCA | $65.23M | 1.3% | -22% shares |
| VIATRIS INC | VTRS | $61.40M | 1.2% | -15% shares |
What changed since Q4 2023
Against the Q4 2023 filing, Glenview Capital Management opened 6 new positions, added to 14, trimmed 14, left 9 unchanged and exited 4. Every position is compared, matched on its CUSIP; a change of 2% or less in shares counts as unchanged.
Other quarters
Source: SEC Form 13F-HR, accession 0000905148-24-001435, filed by GLENVIEW CAPITAL MANAGEMENT, LLC. Values are as filed and cover US-listed positions only; a 13F does not show short positions or holdings outside the US. A 13F may be filed up to 45 days after the quarter ends, so the fund may have traded since. Educational information, not financial advice.